Prestige Plans ‘Strong Price Competitiveness’ For Its Adalimumab Biosimilar
Discloses Phase I Details And Phase III Plans Ahead Of Filings In EU And US
• By David Wallace
Prestige Biopharma believes it can compete on price in the Humira market • Source: Alamy 
